4-amino-1-methylindoline | 801316-05-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 4-amino-1-methylindoline
• 英文别名: 1-methyl-2,3-dihydro-1H-indol-4-amine；1-methyl-2,3-dihydroindol-4-amine
• CAS: 801316-05-2
• 化学式: C₉H₁₂N₂
• mdl: MFCD19207651
• 分子量: 148.208
• InChiKey: LHOKDTHCXJUSEC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1-methyl-4-nitro-2,3-dihydro-1H-indole 在 palladium/active carbon 氢气 作用下， 以 乙醇 为溶剂， 反应 0.33h， 生成 4-amino-1-methylindoline
  参考文献：
  名称：

  [EN] QUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS
  [FR] DERIVES DE QUINOLEINE UTILISES EN TANT QU'INHIBITEURS DE LA PHOSPHODIESTERASE

  摘要：

  根据本发明提供了化合物的新结构，其化学式为（I）或其药用盐，其中R1、R2、R19、R20和R34如规范中所述，以及制备这些化合物的方法、含有它们的配方和它们在治疗炎症性疾病中的用途。

  公开号：

  WO2004103998A1

文献信息

• 7H-PYRROLO[2,3-H]QUINAZOLINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESIS
  申请人：Venkatesan Aranapakam Mudumbai

  公开号：US20090227575A1

  公开（公告）日：2009-09-10

  A 7H-pyrrolo[2,3-h]quinazoline compound of the formula I wherein Ar, R 1 , R 2 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , and n are as defined in the specification, and methods for making same.

  一个7H-吡咯[2,3-h]喹唑啉化合物的公式I 其中Ar，R1，R2，R7，R8，R9，R10，R11，R12和n如说明书中所定义，以及制造相同的方法。
• NOVEL COMPOUNDS
  申请人：Gottschling Dirk

  公开号：US20110195954A1

  公开（公告）日：2011-08-11

  The present invention relates to new CGRP-antagonists of general formula I wherein U, V, X, Y, R 1 , R 2 , R 3 and R 4 are defined as mentioned in the description, the tautomers thereof, the isomers thereof, the diastereomers thereof, the enantiomers thereof, the hydrates thereof, the mixtures thereof and the salts thereof as well as the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, medicaments containing these compounds, the use thereof and processes for the preparation thereof.

  本发明涉及一般式I的新CGRP拮抗剂，其中U、V、X、Y、R1、R2、R3和R4如描述中所述定义，其互变异构体、异构体、顺反异构体、对映异构体、水合物、混合物及其盐，以及其盐的水合物，特别是与无机或有机酸或碱形成的生理上可接受的盐，包含这些化合物的药物、其用途以及其制备方法。
• The effect of substitution on the utility of piperidines and octahydroindoles for reversible hydrogen storage
  作者：Yi Cui、Samantha Kwok、Andrew Bucholtz、Boyd Davis、Ralph A. Whitney、Philip G. Jessop

  DOI：10.1039/b718209k

  日期：——

  Substituted piperidines and octahydroindoles are compared in terms of their usability as reversible organic hydrogen storage liquids for hydrogen-powered fuel cells. Theoretical Gaussian calculations indicate which structural features are likely to lower the enthalpy of dehydrogenation. Experimental results show that attaching electron donating or conjugated substituents to the piperidine ring greatly increases the rate of catalytic dehydrogenation, with the greatest rates being observed with 4-aminopiperidine and piperidine-4-carboxamide. Undesired side reactions were observed with some compounds such as alkyl transfer reactions during the dehydrogenation of 4-dimethylaminopiperidine, C–O and C–N cleavage reactions during hydrogenation and/or subsequent dehydrogenation of 4-alkoxy and 4-amino indoles, and disproportionation during the hydrogenation of 4-aminopyridine.

  替代哌啶和八氢吲哚在可逆有机储氢液方面，作为氢燃料电池的实用性进行了比较。理论高斯计算表明哪些结构特征可能会降低脱氢焓。实验结果显示，将电子供体或共轭取代基连接到哌啶环上大大提高了催化脱氢速率，其中4-氨基哌啶和哌啶-4-甲酰胺的速率最高。观察到了一些不希望的副反应，例如在4-二甲氨基哌啶脱氢过程中发生的烷基转移反应，4-烷氧基和4-氨基吲哚氢化和/或随后脱氢过程中发生的C-O和C-N断裂反应，以及4-氨基吡啶氢化过程中发生的歧化反应。
• Quinoline derivatives as phosphodiesterase inhibitors
  申请人：Barker David Michael

  公开号：US20060178416A1

  公开（公告）日：2006-08-10

  There are provided according to the invention novel compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R19, R20, and R34 are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.

  根据本发明提供了公式(I)的新化合物或其药学上可接受的盐，其中R1、R2、R19、R20和R34如规范所述，以及制备它们的过程、包含它们的制剂和它们在治疗炎症性疾病方面的用途。
• Quinoline Derivatives As Phosphodiesterase Inhibitors
  申请人：Baldwin Ian Robert

  公开号：US20090312325A1

  公开（公告）日：2009-12-17

  There are provided according to the invention novel compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R19, R20, and R34 are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.

  根据本发明提供了一种新的化合物式(I)或其药学上可接受的盐，其中R1、R2、R19、R20和R34如规范所述，以及制备它们的过程、含有它们的制剂以及它们在治疗炎症性疾病方面的用途。